RO6927005

RO6927005 (also known as RG6120) is a bispecific T-cell engager (TCE) developed by Hoffmann-La Roche that targets mesothelin (MSLN) on tumor cells and the CD3 epsilon subunit on T cells. Mesothelin is a cell-surface glycoprotein that is highly overexpressed in several aggressive malignancies, including pancreatic ductal adenocarcinoma (PDAC), malignant pleural mesothelioma (MPM), and ovarian cancer, while showing limited expression in normal tissues. By simultaneously binding to MSLN and the T-cell receptor complex, RO6927005 facilitates the formation of an immunological synapse, leading to the recruitment and activation of cytotoxic T lymphocytes (CTLs) directly at the tumor site. This activation results in the release of perforins and granzymes, inducing tumor cell lysis independent of MHC-I expression. RO6927005 has been evaluated in Phase 1 clinical trials both as a monotherapy and in combination with standard-of-care chemotherapies such as gemcitabine and nab-paclitaxel.

Other names

MSLN-TCBMesothelin-CD3 T-cell bispecific antibodyMesothelin-CD-3 T-cell bispecific antibodyMesothelin-CD 3 T-cell bispecific antibody